American Oriental Bioengineering Announces Undergoing SFDA Directed Inspection of Capsules
NEWARK, N.J., April 19, 2012 /PRNewswire-Asia-FirstCall/ -- American Oriental Bioengineering, Inc. (NYSE: AOB), (the "Company" or "AOB"), a pharmaceutical company dedicated to improving health through the development, manufacture and commercialization of a broad range of prescription and over-the-counter ("OTC") products, today announced that four out of its five manufacturing subsidiaries are undergoing onsite short notice inspections directed by China State Food and Drug Administration ("SFDA"). On 4/16/2012 China SFDA circulated an urgent notice nationwide calling for immediate suspension of sales and manufacturing of certain capsule products, sparked by the discovery of thirteen kinds of capsule products with origins from Qinghai and ...

New Oriental Announces Results for the Third Fiscal Quarter Ended February 29, 2012, and Declares a Special Cash Dividend
BEIJING, April 17, 2012 /PRNewswire-Asia/ -- New Oriental Education and Technology Group Inc. (the "Company" or "New Oriental") (NYSE: EDU), the largest provider of private educational services in China, today announced its unaudited financial results for the fiscal quarter ended February 29, 2012, which is the third quarter of New Oriental's fiscal year 2012. Highlights for the Third Fiscal Quarter Ended February 29, 2012 Total net revenues increased by 31.7% year-over-year to US$174.5 million from US$132.5 million in the same period of the prior fiscal year.

American Oriental Bioengineering Inc. Receives NYSE Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
NEWARK, N.J., April 6, 2012 /PRNewswire-Asia-FirstCall/ -- American Oriental Bioengineering, Inc. (NYSE: AOB) (the "Company") today announced that the New York Stock Exchange (the "NYSE") has notified the Company that it is not in compliance with NYSE rules due to the Company's failure to timely file its Annual Report on Form 10-K with the Securities and Exchange Commission.